2026-06-28T20:28:24Zhttps://docta.ucm.es/rest/oai/request

oai:docta.ucm.es:20.500.14352/1162272025-03-18T14:51:02Zcom_20.500.14352_14col_20.500.14352_15

Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer Morán, Alberto García-Aranda, Carmen Díaz-López, Antonio Iniesta Serrano, María Pilar Juan Chocano, María Del Carmen De Sánchez Pernaute, Andrés Torres García, Antonio José Díaz-Rubio García, Eduardo Balibrea Cantero, José Luis Benito De Las Heras, Manuel R. The main aim of this study was to evaluate the clinical relevance of Gelatinases in colorectal cancer (CRC). Ninety-five CRCs and their paired normal tissues were investigated to detect total levels of MMP-9, MMP-2, and the tissue inhibitors TIMP-1 and TIMP-2. Also, pro-MMP and MMP activity, and potential associations with clinical parameters were estimated. MMP-9, MMP-2 and TIMP-1 levels were greater in CRCs than in normal tissues, differences being significant for MMP-9 and TIMP-1. However, TIMP-2 showed significantly lower levels in tumour samples. Moreover, significant differences in the state of activation between gelatinases were found. TIMP-1 low levels were significantly associated with poor clinical outcome of patients. According to these data, different roles have to be attributed to MMP-2 and MMP-9 in CRC progression. Moreover, TIMP-1 level evaluation emerges as the main prognostic factor in relation to Gelatinases A and B activity in CRC. 2025-01-27T11:09:52Z 2025-01-27T11:09:52Z 2025-01-27T11:09:52Z 2005 journal article https://hdl.handle.net/20.500.14352/116227 1021-335X 10.3892/or.13.1.115 1791-2431 eng Morán A, Iniesta P, García-Aranda C, De Juan C, Díaz-López A, Sánchez- Pernaute A, Torres AJ, Díaz-Rubio E, Balibrea JL, Benito M. Clinical relevance of MMP-9, MMP-2, TIMP-1 and TIMP-2 in colorectal cancer. Oncol Rep. 2005 Jan;13(1):115-20. PMID: 15583811. http://creativecommons.org/licenses/by/4.0/ restricted access Attribution 4.0 International SPANDIDOS PUBL LTD